Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations

NCT06151574 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06151574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06151574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 9, 2024
Completion date
January 28, 2028
Enrollment
428 (actual)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-squamous, non-small cell